New research from the Karolinska Institute indicates that high blood sugar, a common feature of diabetes and metabolic syndrome, may impair the immune system’s ability to detect and destroy cancer cells. The findings, published this month in a peer-reviewed journal, add to a growing body of evidence linking metabolic health to cancer outcomes and may explain in part why patients with diabetes face higher risks for several malignancies.
The study, conducted by researchers in Stockholm, examined how elevated glucose levels affect the function of T cells, the immune system’s primary cancer-fighting agents. According to the report, cancer cells themselves appear to use excess sugar as a shield, suppressing the activity of nearby immune cells and reducing the visibility of tumors to immune surveillance.
“The metabolism of immune cells is very important for their function,” said the research team in a statement summarizing the work. “If cancer cells consume a lot of sugar, they can starve T cells of energy and nutrients, which weakens the immune response.”
Analysis: The study’s findings are notable because they suggest a direct mechanism linking blood sugar control to cancer immunity. By showing that cancer cells can outcompete T cells for glucose, the research reframes hyperglycemia not just as a marker of poor health, but as an active participant in tumor immune evasion.
What happened
Researchers at Karolinska Institute found that breast cancer cells grown in high-glucose environments produced signals that reduced the ability of T cells to recognize and attack tumors. The immune cells, deprived of fuel, showed diminished activity compared to T cells exposed to normal sugar levels.
The team reported that elevated glucose also appeared to alter the chemical environment around tumors, increasing levels of immunosuppressive metabolites. Together, these effects created conditions under which cancer cells could proliferate with reduced interference from the immune system.
“This is a previously underappreciated way in which blood sugar can influence cancer progression,” the researchers said.
Why it matters
The findings carry significant implications for both cancer prevention and treatment. Diabetes and prediabetes affect more than half a billion adults globally, according to the International Diabetes Federation. If elevated blood sugar actively contributes to immune evasion, then glycemic control could become a meaningful part of oncology care.
For patients with both diabetes and cancer, the study raises questions about whether tighter glucose management could improve the effectiveness of immunotherapies such as checkpoint inhibitors, which rely on robust T cell function. Existing clinical trials have already begun exploring metformin, a common diabetes drug, as a potential adjunct to cancer immunotherapy, though results have been inconclusive.
Analysis: If validated in human trials, the Karolinska findings could shift how oncologists think about supportive care for diabetic cancer patients. Glycemic control, often treated as a secondary concern in oncology, might emerge as a modifiable factor influencing treatment response.
Background and context
The relationship between diabetes and cancer has been studied for decades. Epidemiological research has consistently shown that people with type 2 diabetes face elevated risks for cancers of the breast, colon, pancreas, liver, and endometrium. However, the mechanisms behind these associations have remained debated.
Some researchers have attributed the link to shared risk factors such as obesity, chronic inflammation, and insulin resistance. Others have pointed to potential direct effects of high blood sugar, insulin, or related hormones on tumor growth. The Karolinska study adds weight to the latter explanation by demonstrating a specific immune-related pathway.
The work builds on earlier studies showing that tumor cells rewire their metabolism to support rapid growth, a phenomenon known as the Warburg effect. Cancer cells typically consume glucose at far higher rates than normal tissue, producing lactate as a byproduct. The Karolinska team found that this lactate buildup, accelerated by high sugar, further suppresses T cell function.
“This study contributes to a growing understanding that metabolic competition between cancer cells and immune cells is a key driver of disease progression,” the authors wrote.
Analysis: The findings align with a broader shift in cancer research toward understanding the tumor microenvironment, the cellular and chemical surroundings in which tumors develop. Metabolic competition is increasingly viewed as a critical battleground, alongside more established factors such as genetic mutations and immune checkpoints.
What to watch next
Several follow-up questions remain. The Karolinska study was conducted in cell cultures and animal models, meaning human trials will be necessary to confirm whether blood sugar management meaningfully alters cancer outcomes in patients.
Researchers will likely explore whether specific glucose thresholds trigger the immunosuppressive effects observed in the study. There may also be interest in testing whether existing diabetes medications, including metformin and GLP-1 receptor agonists, can restore T cell function in cancer patients.
Additionally, the study’s findings could inform the design of combination therapies pairing metabolic interventions with immunotherapies. Several early-stage clinical trials are already investigating such approaches.
Analysis: For policymakers and health systems, the research underscores the importance of diabetes prevention and management as public health priorities, not only for cardiovascular and metabolic reasons but potentially for cancer outcomes as well.
Conclusion
The Karolinska Institute study provides fresh evidence that blood sugar levels can directly influence how the immune system responds to cancer. By demonstrating that tumors exploit glucose to suppress T cells, the research points to a potentially modifiable factor in cancer progression, one that affects a large and growing patient population.
As research advances, the findings may encourage oncologists to pay closer attention to the metabolic health of their patients and prompt new clinical trials exploring how glycemic control could enhance the effectiveness of cancer immunotherapy.
Analysis: The broader takeaway is that cancer is not solely a genetic disease but also a metabolic one. Interventions targeting metabolism, long used in diabetes care, may find a second life in oncology, offering new tools in the fight against tumors that have learned to hide from the immune system.
Sources
Karolinska Institute study on blood sugar and cancer immune evasion
Source: Science Daily
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Science Daily — source
